MARLBOROUGH, Mass.,
June 4, 2015 /PRNewswire/ -- Boston
Scientific announces the European launch of the Precision Novi™
Spinal Cord Stimulator (SCS) System at the International
Neuromodulation Society in Montreal,
Canada. The 16-contact primary cell device has CE Mark for
the treatment of chronic pain, and is the smallest high-capacity
primary cell device currently available. The enhanced shape of the
Precision Novi implant is designed to provide a new level of
comfort to patients with pain treated using primary cell therapy.
Precision Novi is powered by Illumina 3D™ Software that enables
physicians to target pain precisely with point-and-click
simplicity.
Chronic pain can have a devastating impact on quality of life
for many patients. Spinal cord stimulators alleviate pain by
stimulating the nerve fibers in the spinal cord to reduce pain
signals. While primary cell (also referred to as non-rechargeable)
devices are typically larger due to limitations in technology and
battery size, the Precision Novi System represents a significant
technology advance, with the smallest high-capacity battery on the
market, allowing effective pain relief to be delivered from a much
smaller device. The Precision Novi System is also the only primary
cell device that couples with a wireless remote , empowering
patients with flexibility and control over their pain management.
"The small size and novel shape of the Precision Novi implant
improves patient comfort and enables a very discreet subcutaneous
placement," said Dr. Simon Thomson,
a consultant in Pain Management and Neuromodulation at Basildon and
Thurrock University Hospitals, UK. "The simplicity of the
programming software saves valuable time in the operating theatre,
efficiently allowing me to achieve and maintain comfortable therapy
for my patients."
Unlike any other primary cell system, the Precision Novi
intuitive Illumina 3D neural targeting software incorporates
three-dimensional lead location, as well as the conductivity of the
spinal cord and surrounding tissue. This point-and-click technology
automatically calculates the optimal programming configuration to
target the selected pain area. Further, unique for primary cell
devices, Precision Novi is a MultiWave™ Platform capable of
delivering a variety of field shapes and waveforms with or without
paresthesia, including burst and higher rate frequencies.
"We are excited to expand upon our range of therapeutic
solutions for patients suffering from chronic pain," said
Maulik Nanavaty, president,
Neuromodulation, Boston Scientific. "The Precision Novi System
brings the power of our Illumina 3D Algorithm to the more than
sixty percent of SCS patients in Europe who are treated with primary cell
therapy."
The Precision Novi SCS System is not available in the United States. Comparative statements true
as of June 4, 2015.
About Boston Scientific
Boston Scientific transforms lives through innovative medical
solutions that improve the health of patients around the
world. As a global medical technology leader for more than 35
years, we advance science for life by providing a broad range of
high performance solutions that address unmet patient needs and
reduce the cost of healthcare. For more information, visit
www.bostonscientific.com and connect on Twitter and Facebook.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934.
Forward-looking statements may be identified by words like
"anticipate," "expect," "project," "believe," "plan," "estimate,"
"intend" and similar words. These forward-looking statements
are based on our beliefs, assumptions and estimates using
information available to us at the time and are not intended to be
guarantees of future events or performance. These
forward-looking statements include, among other things, statements
regarding product launches, product performance and impact, and
competitive offerings. If our underlying assumptions turn out
to be incorrect, or if certain risks or uncertainties materialize,
actual results could vary materially from the expectations and
projections expressed or implied by our forward-looking statements.
These factors, in some cases, have affected and in the future
(together with other factors) could affect our ability to implement
our business strategy and may cause actual results to differ
materially from those contemplated by the statements expressed in
this press release. As a result, readers are cautioned not to
place undue reliance on any of our forward-looking statements.
Factors that may cause such differences include, among other
things: future economic, competitive, reimbursement and regulatory
conditions; new product introductions; demographic trends;
intellectual property; litigation; financial market conditions;
and, future business decisions made by us and our competitors.
All of these factors are difficult or impossible to predict
accurately and many of them are beyond our control. For a
further list and description of these and other important risks and
uncertainties that may affect our future operations, see Part I,
Item 1A – Risk Factors in our most recent Annual Report on
Form 10-K filed with the Securities and Exchange Commission, which
we may update in Part II, Item 1A – Risk Factors in
Quarterly Reports on Form 10-Q we have filed or will file
hereafter. We disclaim any intention or obligation to
publicly update or revise any forward-looking statements to reflect
any change in our expectations or in events, conditions, or
circumstances on which those expectations may be based, or that may
affect the likelihood that actual results will differ from those
contained in the forward-looking statements. This cautionary
statement is applicable to all forward-looking statements contained
in this document.
CONTACT:
Nisha Deo
408-893-9243 (cell)
External Communications
Boston Scientific Corporation
Nisha.Deo@bsci.com
Susie Lisa, CFA
508-683-5565 (office)
Investor Relations
Boston Scientific Corporation
investor_relations@bsci.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/boston-scientific-launches-the-precision-novi-spinal-cord-stimulator-system-in-europe-300094098.html
SOURCE Boston Scientific Corporation